These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 30471652)

  • 21. An open-label, prospective trial to evaluate the efficacy and safety of ixazomib in combination with cyclophosphamide and dexamethasone in patients with newly diagnosed POEMS syndrome.
    He H; Hou N; Chen X; Song Y; Qiang W; Liu J; Lu J; Fu W; Du J
    Br J Haematol; 2024 Aug; 205(2):478-482. PubMed ID: 38955502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical Efficacy and Safety of Ixazomib-Containing Regimens in the Treatment of Patients with Multiple Myeloma].
    Chen R; Xue LG; Zhou H; Jia T; Cai ZM; Zhu YX; Miao L; Wei JF; Zhao LD; Mao JP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):483-492. PubMed ID: 38660856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
    Hájek R; Minařík J; Straub J; Pour L; Jungova A; Berdeja JG; Boccadoro M; Brozova L; Spencer A; van Rhee F; Vela-Ojeda J; Thompson MA; Abonour R; Chari A; Cook G; Costello CL; Davies FE; Hungria VT; Lee HC; Leleu X; Puig N; Rifkin RM; Terpos E; Usmani SZ; Weisel KC; Zonder JA; Bařinová M; Kuhn M; Šilar J; Čápková L; Galvez K; Lu J; Elliott J; Stull DM; Ren K; Maisnar V
    Future Oncol; 2021 Jul; 17(19):2499-2512. PubMed ID: 33769076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
    Dimopoulos MA; Špička I; Quach H; Oriol A; Hájek R; Garg M; Beksac M; Bringhen S; Katodritou E; Chng WJ; Leleu X; Iida S; Mateos MV; Morgan G; Vorog A; Labotka R; Wang B; Palumbo A; Lonial S;
    J Clin Oncol; 2020 Dec; 38(34):4030-4041. PubMed ID: 33021870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma.
    Li S; Zhang D; Yang L; Huang C; Niu T; Gong Y
    Cancer Med; 2023 Mar; 12(6):6523-6535. PubMed ID: 36377601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
    Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
    Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
    Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
    Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.
    Tanaka K; Toyota S; Akiyama M; Wakimoto N; Nakamura Y; Najima Y; Doki N; Kakihana K; Igarashi A; Kobayashi T; Ohashi K; Kudo D; Shinagawa A; Takano H; Fujio T; Okoshi Y; Hori M; Kumagai T; Saito T; Mukae J; Yamamoto K; Tsutsumi I; Komeno T; Yoshida C; Yamamoto M; Kojima H;
    Acta Haematol; 2019; 141(2):111-118. PubMed ID: 30726834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.
    Shen M; Zhang J; Tang R; Wang Y; Zhan X; Fan S; Huang Z; Zhong Y; Li X
    Cancer Med; 2022 Jun; 11(11):2173-2183. PubMed ID: 34655168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
    Belch A; Bahlis N; White D; Cheung M; Chen C; Shustik C; Song K; Tosikyan A; Dispenzieri A; Anderson K; Brown D; Robinson S; Srinivasan S; Facon T
    Cancer Med; 2020 Dec; 9(23):8923-8930. PubMed ID: 33049118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
    Kumar SK; LaPlant BR; Reeder CB; Roy V; Halvorson AE; Buadi F; Gertz MA; Bergsagel PL; Dispenzieri A; Thompson MA; Crawley J; Kapoor P; Mikhael J; Stewart K; Hayman SR; Hwa YL; Gonsalves W; Witzig TE; Ailawadhi S; Dingli D; Go RS; Lin Y; Rivera CE; Rajkumar SV; Lacy MQ
    Blood; 2016 Nov; 128(20):2415-2422. PubMed ID: 27702799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
    Isa R; Uoshima N; Takahashi R; Nakano-Akamatsu S; Kawata E; Kaneko H; Shimura K; Kamitsuji Y; Takimoto-Shimomura T; Mizutani S; Chinen Y; Ohshiro M; Fujino T; Kawaji Y; Uchiyama H; Sasaki N; Tsukamoto T; Shimura Y; Kobayashi T; Taniwaki M; Kuroda J;
    Ann Hematol; 2020 Jan; 99(1):137-145. PubMed ID: 31768675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.
    Muchtar E; Gertz MA; LaPlant BR; Buadi FK; Leung N; O'Brien P; Bergsagel PL; Fonder A; Hwa YL; Hobbs M; Helgeson DK; Bradt EE; Gonsalves W; Lacy MQ; Kapoor P; Siddiqui M; Larsen JT; Warsame R; Hayman SR; Go RS; Dingli D; Kourelis TV; Dispenzieri A; Rajkumar SV; Kumar SK
    Blood Adv; 2022 Sep; 6(18):5429-5435. PubMed ID: 35737873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
    Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S
    Blood Cancer J; 2022 Jan; 12(1):9. PubMed ID: 35075109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
    Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
    Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
    Suzuki K; Handa H; Chou T; Ishizawa K; Takubo T; Kase Y
    Int J Hematol; 2017 Apr; 105(4):445-452. PubMed ID: 28000099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
    Terpos E; Ramasamy K; Maouche N; Minarik J; Ntanasis-Stathopoulos I; Katodritou E; Jenner MW; Plonkova H; Gavriatopoulou M; Vallance GD; Pika T; Kotsopoulou M; Kothari J; Jelinek T; Kastritis E; Aitchison R; Dimopoulos MA; Zomas A; Hajek R
    Ann Hematol; 2020 May; 99(5):1049-1061. PubMed ID: 32236735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.
    Muranushi H; Kanda J; Kobayashi M; Maeda T; Kitano T; Tsuji M; Ueda Y; Ishikawa T; Nohgawa M; Watanabe M; Imada K; Moriguchi T; Itoh M; Ohno H; Yonezawa A; Hirata H; Arima N; Asagoe K; Anzai N; Nagata K; Yasuno S; Kuwabara Y; Kitao H; Kim I; Kawagishi K; Ueshima K; Tominari S; Nakayama T; Yamashita K; Takaori-Kondo A
    Hematology; 2022 Dec; 27(1):239-248. PubMed ID: 35152852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
    Hinsley S; Walker K; Sherratt D; Bailey L; Reed S; Flanagan L; McKee S; Brudenell Straw F; Dawkins B; Meads D; Auner HW; Kaiser MF; Cook M; Brown S; Cook G;
    Trials; 2020 Oct; 21(1):826. PubMed ID: 33008427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.
    Bringhen S; D'Agostino M; De Paoli L; Montefusco V; Liberati AM; Galieni P; Grammatico S; Muccio VE; Esma F; De Angelis C; Musto P; Ballanti S; Offidani M; Petrucci MT; Gaidano G; Corradini P; Palumbo A; Sonneveld P; Boccadoro M
    Leukemia; 2018 Apr; 32(4):979-985. PubMed ID: 29263440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.